1508 - Pembrolizumab (MK-3475) in Mismatch Repair Deficient (dMMR) Stage IV Solid tumours other than colorectal cancer

Page last updated: 04 October 2017

Application Detail

Status

Open

Description of Medical Service

The proposed medical service is an ImmunoHistoChemistry (IHC) test for identification of dMMR for access to pembrolizumab in patients with metastatic or unresectable solid tumours other than colorectal cancers.

Description of Medical Condition

Patients with unresectable or metastatic solid tumours other than colorectal cancer which are mismatch repair deficient (dMMR) who have progressed following prior treatment

Reason for Application

Amendment to MBS item

Medical Service Type

Investigative

Previous Application Number

Not Applicable

Associated Documentation

Application Form

Application Form (Word 162 KB)
Application Form (PDF 1030 KB)

Consultation Survey

Consultation Survey (Word 508 KB)
Consultation Survey (PDF 311 KB)

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

7-8 December 2017

ESC

-

MSAC

-